Early diagnosis is key. Similar to other disorders such as breast cancer and heart disease, identifying disease in the early clinical stages allow for more options and new treatment. 

Dr. Moon has brought advanced testing early into DNC and has been performing FDG PET scans for over a decade and have been early in biomarker testing to detect Alzheimer’s. Participating in clinical trials have allowed our patients access to the therapies of the future.

Dr. Moon has been a national consultant on the development of the medication ADUHELM (Biogen) and is currently consulting on the medications LEQEMBI (Eisai) and future therapy DONANEMAB (Lilly). DNC is one of the first centers in the United States to use ADUHELM and LEQEMBI.